55095-27-7

Upstream product

• 363-02-0 4,4’-difluorobenzophenone oxime 
• 345-92-6 4,4'-Difluorobenzophenone 
• 362-99-2 (4-fluorophenyl)-phenylmethanone oxime 
• 7705-07-9 titanium(III) chloride 
• 81123-44-6 (4-hydroxyphenyl)(phenyl)methanone oxime 
• 457-68-1 4,4'-difluorodiphenylmethane 
• 1194-02-1 4-fluorobenzonitrile 
• 80529-17-5 4,4'-difluorobenzophenone imine 
• 352-13-6 4-flourophenylmagnesium bromide 
• 648893-89-4 N-[bis(4-fluorophenyl)methyl]formamide 
• 365-24-2 4,4'-difluorobenzhydryl alcohol 
• 285129-93-3 Phenyl N-(4,4'-difluorobenzhydryl)carbamate 

Downstream Products

• 88535-59-5 N,N'-Diallyl-6-(4-{[bis-(4-fluoro-phenyl)-methyl]-amino}-piperidin-1-yl)-[1,3,5]triazine-2,4-diamine 
• 141528-05-4 N-Allyl-6-(4-{[bis-(4-fluoro-phenyl)-methyl]-amino}-piperidin-1-yl)-N'-propyl-[1,3,5]triazine-2,4-diamine 
• 88535-72-2 6-(4-{[Bis-(4-fluoro-phenyl)-methyl]-amino}-piperidin-1-yl)-N,N'-bis-((E)-but-2-enyl)-[1,3,5]triazine-2,4-diamine 
• 88551-62-6 N²,N⁴-Diallyl-6-(4-{[bis-(4-fluoro-phenyl)-methyl]-amino}-piperidin-1-yl)-pyrimidine-2,4-diamine 
• 1026196-20-2 (1S,3aS,3bS,9aR,9bS,11aS)-1-{[Bis-(4-fluoro-phenyl)-methyl]-carbamoyl}-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,7,8,9,9a,9b,10,11,11a-tetradecahydro-cyclopenta[i]phenanthridine-5-carboxylic acid tert-butyl ester 
• 116574-15-3 1-[Bis-(4-fluoro-phenyl)-methyl]-azetidin-3-ol 
• 896127-64-3 tert-butyl 3-(2-{[bis(4-fluorophenyl)methyl]amino}-2-oxoethyl)pyrrolidine-1-carboxylate 
• 696588-18-8 tert-butyl-4-(2-{[bis(4-fluorophenyl)methyl]amino}-2-oxoethyl)piperidine-1-carboxylate 
• 1350710-24-5 (1R,2R,4R)-N-[bis(4-fluorophenyl)methyl]-2-(4-bromophenyl)-4-(morpholin-4-yl)cyclohexanecarboxamide 
• 1350711-03-3 2-{[(1R,3R,4R)-4-({[bis(4-fluorophenyl)methyl]amino}carbonyl)-3-(4-bromophenyl)cyclohexyl]-amino}-N,N-diethyl-2-oxoethanamine 
• 345-92-6 4,4'-Difluorobenzophenone 

Relevant academic research and scientific papers

Electrochemical Oxidative C(sp3)-H/N-H Coupling of Diarylmethanes with Sulfoximines or Benzophenone Imine

Herein, we report an efficient electrochemical method for the synthesis of N-alkylated sulfoximines by electrochemical oxidative C(sp3)-H/N-H coupling of sulfoximines and diarylmethanes. In addition, we used the same conditions for electrochemical dehydrogenative amination of diarylmethanes with benzophenone imine as an aminating agent. The reactions showed good functional group tolerance and afforded the corresponding products in moderate to good yields without the use of a stoichiometric oxidant, a metal catalyst, or an activating agent.

Hydrogen bond directed aerobic oxidation of amines via photoredox catalysis

An application of H-bonding interactions for directing the α-C-H oxidation of amines to amides and amino-ketones catalyzed by an organic photocatalyst is reported. The high efficiency of this method is demonstrated by the aerobic oxidation of pyrrolidines, diarylamines and benzylamines bearing urea groups with high yields and a wide substrate scope.

2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD)

The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.

DOPAMINE D2 RECEPTOR LIGANDS

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.

SUBSTITUTED PYRIMIDINES

Disclosed are substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

SUBSTITUTED PYRIMIDINES

The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors

The synthesis, SAR, binding affinities and pharmacokinetic profiles are described for a series of cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors discovered by high throughput screening. Compounds show high levels of ex vivo target engagement in mouse plasma 20 h post oral dose.

COMPOUNDS AND METHODS

The present invention relates to novel retinoid-reiated orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.

BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS

The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.

Mapping the active site in a chemzyme: Diversity in the N-substituent in the catalytic asymmetric aziridination of imines

(Chemical Equation Presented) The active site of the aziridination catalyst derived from either the VANOL or VAPOL ligand and B(OPh)3 is larger than expected and can accommodate not only significant substitution on the diarylmethyl unit of the imine but also that alkyl (but not perfluorylalkyl) substituents on the aryl groups lead to enhanced rates and enantioselection. The screen of diarylmethyl N-substituents on the imine revealed that the 3,5-di-tert-butyldianisylmethyl group (BUDAM) gave exceptionally high asymmetric inductions for imines of aryl aldehydes.